Diphtheria: all 267 studies
Page 3 of 3. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineCompletedNCT01457560Phase 3
- Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CourseCompletedNCT01457547Phase 4
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyCompletedNCT01457508Phase 3
- Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyCompletedNCT01457495Phase 2
- Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)CompletedNCT01294605Phase 4
- Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or OlderCompletedNCT01287949Phase 3
- Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®CompletedNCT01277705Phase 3
- Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy AdultsCompletedNCT01267058Phase 3
- Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years OldCompletedNCT01249183Phase 3
- Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.CompletedNCT01214889Phase 3
- Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control VaccineCompletedNCT01105559
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy InfantsCompletedNCT01062477Phase 3
- Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™CompletedNCT01061541Phase 2
- Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of AgeCompletedNCT01031303Phase 4
- A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)WithdrawnNCT01003431Phase 3
- Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable DiseaseStatus unknownNCT00932269
- Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy InfantsCompletedNCT00879827Phase 3
- Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination VaccineStatus unknownNCT00877357Phase 4
- An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine BoosterStatus unknownNCT00870350Phase 4
- Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseCompletedNCT00855855
- Database Surveillance Safety Study of PENTACEL® VaccineCompletedNCT00804284
- Pertussis Vaccine in Healthy Pregnant WomenCompletedNCT00707148Phase 1
- Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineCompletedNCT00674908Phase 4
- Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccineCompletedNCT00662870Phase 3
- Safety and Immunogenicity Study of a Liquid Pentavalent Combination VaccineCompletedNCT00617812Phase 4
- Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.TerminatedNCT00544271Phase 4
- Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of AgeCompletedNCT00524732
- Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio VaccineCompletedNCT00514059Phase 4
- Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 MonthsCompletedNCT00453570Phase 3
- Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT VaccineCompletedNCT00452686Phase 3
- REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old ChildrenCompletedNCT00447525Phase 3
- Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.CompletedNCT00406562Phase 3
- Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of AgeCompletedNCT00379977Phase 3
- Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgeCompletedNCT00376779Phase 2
- Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®CompletedNCT00362427Phase 2
- Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedNCT00355654Phase 3
- Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).CompletedNCT00352963Phase 3
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
- Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/HibCompletedNCT00332566Phase 3
- Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy InfantsCompletedNCT00320463Phase 3
- Immunogenicity and Safety of Tetraxim Versus Local DTP + IPVCompletedNCT00319852Phase 3
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.CompletedNCT00317187Phase 3
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.CompletedNCT00317174Phase 2
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.CompletedNCT00317161Phase 3
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.CompletedNCT00317135Phase 3
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at BirthCompletedNCT00317122Phase 3
- Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.TerminatedNCT00316680Phase 3
- Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination SchedulesCompletedNCT00316147Phase 3
- Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488CompletedNCT00307567Phase 2
- Post-marketing Safety Study of GSK Biologicals' Boostrix® VaccineCompletedNCT00297856
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to InfantsCompletedNCT00291967Phase 2
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy InfantsCompletedNCT00290303Phase 3
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
- Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and SafetyCompletedNCT00263692Phase 2
- Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.CompletedNCT00263679Phase 3
- Immunogenicity and Safety of Pentaxim™ in an Indian PopulationCompletedNCT00259337Phase 3
- Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandCompletedNCT00255021Phase 4
- Immunogenicity and Safety of Pentaxim in South African InfantsCompletedNCT00254969Phase 3
- Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesCompletedNCT00254917Phase 4
- Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in InfantsCompletedNCT00197275Phase 3
- Vaccination of Children Following Allogeneic Stem Cell TransplantationCompletedNCT00169728Phase 3
- Immunology of Non-specific Effects of VaccineCompletedNCT00168545Phase 4
- Post-marketing Safety Study of GSK Biological's Pediarix™ VaccineCompletedNCT00146835
- Pilot Study Freeze and Transport Immune CellsCompletedNCT00138268
- Pentavalent DTaP-Hep B-IPVCompletedNCT00133445Phase 2
- A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td VaccineCompletedNCT00109330Phase 3
- Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)CompletedNCT00092469Phase 3